<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evinacumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evinacumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Evinacumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="130778" href="/d/html/130778.html" rel="external">see "Evinacumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="130816" href="/d/html/130816.html" rel="external">see "Evinacumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55504251"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Evkeeza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58960997"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Evkeeza</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55487251"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F55504314"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="410f3e65-0238-4043-bd1a-1d1166ebc78d">Homozygous familial hypercholesterolemia, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia, adjunct:</b> Children ≥5 years and Adolescents: IV: 15 mg/kg/dose every 4 weeks; use in combination with other low-density lipoprotein-cholesterol (LDL-C) lowering therapies.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55504315"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate:</i> No dosage adjustment necessary. Observed trough concentrations were comparable between patients with mild to moderate renal function and patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe:</i> There are no dosage adjustments are provided in the manufacturer's labeling (has not been studied); dosage adjustment is unlikely to be required as monoclonal antibodies are not known to be renally eliminated.</p></div>
<div class="block dohp drugH1Div" id="F55609863"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no dosage adjustments are provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55608310"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="130778" href="/d/html/130778.html" rel="external">see "Evinacumab: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Refer patient to a lipid specialist prior to use. Consider for use in patients with baseline low-density lipoprotein cholesterol ≥190 mg/dL who have an inadequate response to statins with or without ezetimibe and PCSK9 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 15 mg/kg every 4 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> Administer as soon as possible, then schedule every 4 weeks from the date of last dose.</p></div>
<div class="block dora drugH1Div" id="F55608312"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment is unlikely to be required as monoclonal antibodies are not known to be renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F55608313"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55877161"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">
<b>Severe hypersensitivity reactions</b>, including <b>anaphylaxis,</b> have occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003472'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55487550"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Nasopharyngitis (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;3%), constipation (&lt;3%), nausea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Severe hypersensitivity reaction (including anaphylaxis [1%])<span class="lexi-table-link-container"> (<a aria-label="Anaphylaxis table link" class="lexi-table-link" data-table-id="lexi-content-anaphylaxis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anaphylaxis')">table 1</a>)</span><span class="table-link" style="display:none;">Anaphylaxis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anaphylaxis" frame="border" id="lexi-content-anaphylaxis" rules="all">
<caption style="text-align:center;">
<b>Evinacumab: Adverse Reaction: Anaphylaxis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evinacumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evinacumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (4%), dizziness (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (7%), nasal congestion (&lt;3%), rhinorrhea (5%), upper respiratory tract infection (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion-related reaction (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Decreased diastolic blood pressure (transient), increased heart rate (transient)</p></div>
<div class="block coi drugH1Div" id="F55487153"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity (eg, anaphylaxis) to evinacumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55608286"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have occurred. Discontinue treatment and initiate supportive treatment in patients who develop serious allergic reaction; monitor until symptoms resolve.</p></div>
<div class="block foc drugH1Div" id="F55504252"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evkeeza: Evinacumab-dgnb 1200 mg/8 mL (150 mg/mL) (8 mL); Evinacumab-dgnb 345 mg/2.3 mL (150 mg/mL) (2.3 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F55504250"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55533294"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Evkeeza Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">345MG/2.3ML (per mL): $6,084.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1200 mg/8 mL (per mL): $6,084.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58960998"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evkeeza: 150 mg/mL (2.3 mL, 8 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F55504317"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Must be diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature prior to administration. Administer IV over 60 minutes using an inline or add on 0.2-micron to 5-micron filter. Slow, interrupt, or discontinue infusion and treat as appropriate if patient develops adverse reaction or infusion reaction (eg, infusion site pruritus, pyrexia, muscular weakness, nausea, nasal congestion). Discontinue and provide emergency care if serious or life-threatening hypersensitivity reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If dose is missed, administer as soon as possible and reschedule subsequent dose from date of last dose.</p></div>
<div class="block adm drugH1Div" id="F55608314"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Do not shake. If refrigerated, allow diluted solution to come to room temperature prior to administration; otherwise administer immediately after preparation. Administer IV infusion over 60 minutes through an IV line containing a sterile, in-line or add-on, 0.2-micron to 5-micron filter. May administer without regard to timing of lipoprotein apheresis. Rate of infusion may be slowed, interrupted, or discontinued if patient develops any adverse reactions, including infusion or hypersensitivity reactions.</p></div>
<div class="block sts drugH1Div" id="F55608301"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vial at 2ºC to 8ºC (36ºF to 46ºF). Store the vial in the original carton to protect from light. Do not freeze. Do not shake. Does not contain a preservative. If not used immediately, store the diluted solution at 2ºC to 8ºC (36ºF to 46ºF) for ≤24 hours from the time of preparation <b>or</b> at room temperature up to 25ºC (77ºF) for ≤6 hours from the time of infusion preparation to the end of the infusion. Do not freeze the vials or diluted solution.</p></div>
<div class="block usep drugH1Div" id="F55487252"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of homozygous familial hypercholesterolemia, as an adjunct to other low-density lipoprotein-cholesterol lowering therapies (FDA approved in ages ≥5 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F55504405"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55504402"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55608283"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who may become pregnant. Patients who may become pregnant should use effective contraception during therapy and for at least 5 months after the last evinacumab dose.</p></div>
<div class="block pri drugH1Div" id="F55608284"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to evinacumab may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Evinacumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block mopp drugH1Div" id="F55504318"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assess low-density lipoprotein-cholesterol (LDL-C) when clinically appropriate; low-density lipoprotein lowering may be measured as early as 2 weeks after initiating therapy; signs/symptoms of hypersensitivity reactions; pregnancy test prior to initiation of therapy.</p></div>
<div class="block pha drugH1Div" id="F55608303"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 inhibits lipoprotein lipase (LPL) and endothelial lipase (EL). ANGPTL3 inhibition by evinacumab results in increased lipid metabolism, leading to decreased low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglycerides (TG). Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor by promoting very low-density lipoprotein processing and clearance upstream of LDL formation. Evinacumab-dgnb blockade of ANGPTL3 lowers TG and HDL-C by rescuing LPL and EL activities, respectively.</p></div>
<div class="block phk drugH1Div" id="F55608304"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~4.7 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Function of evinacumab serum concentration; median time of 20 weeks for serum concentration to decrease below lower quantification limit.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Not likely to undergo renal excretion.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216492"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Evkeeza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Evkeeza (evinacumab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evinacumab-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34003472">
<a name="34003472"></a>Markham A. Evinacumab: first approval. <i>Drugs</i>. 2021;10.1007/s40265-021-01516-y. doi:10.1007/s40265-021-01516-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evinacumab-pediatric-drug-information/abstract-text/34003472/pubmed" id="34003472" target="_blank">34003472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evinacumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evinacumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 130801 Version 38.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
